2023 年半年度募集资金存放与实际使用情况专项报告的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性依法承担法律责任。 上海复旦张江生物医药股份有限公司（以下简称"公司"）根据中国证券监督管理委员会 《上市公司监管指引第2号—上市公司募集资金管理和使用的监管要求》《上海证券交易所 科创板股票上市规则》及《上海证券交易所科创板上市公司自律监管指引第1号——规范运 作》等相关规定要求，现将2023年半年度（以下简称"本报告期"）募集资金存放与实际使 用情况报告如下： 一、募集资金基本情况 股票代码：688505 股票简称：复旦张江 编号：临2023-043 上海复旦张江生物医药股份有限公司 （一）实际募集资金的金额及到账情况 根据中国证券监督管理委员会于2020年5月14日出具的《关于同意上海复旦张江生物医 药股份有限公司首次公开发行股票注册的批复》（证监许可[2020]912号），同意上海复旦 张江生物医药股份有限公司首次公开发行股票的注册申请。公司本次公开发行人民币普通 股 120,000,000 股 ， 本 次 发 行 价 格 为 ...

股票代码：688505 股票简称：复旦张江 编号：临 2023-041 上海复旦张江生物医药股份有限公司 自愿披露关于注射用 FZ-AD004 抗体偶联剂用于治疗晚期实体瘤 I 期临床试验完成首例受试者入组的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海复旦张江生物医药股份有限公司（以下简称"公司"）研发的注射用 FZ-AD004 抗体偶联剂（即抗 Trop2 抗体偶联 BB05，以下简称"该药物"）用于 治疗晚期实体瘤的药物 I 期临床研究于近日成功完成首例受试者入组。 一、 药物的相关情况 近年来，公司在小分子端构建了全新的拥有自主知识产权的 Linker-Drug 平 台（以下简称"BB05 平台"）。该药物是 BB05 平台第二个新一代抗体偶联药物 （antibody-drug conjugate，ADC），由针对人滋养层细胞表面糖蛋白抗原（以下 简称"TROP-2"）靶点的单克隆抗体与 BB05 偶联组成。TROP-2 在人体正常组 织中有不同水平的表达，但在如乳腺癌、肺癌、胃癌等多种肿瘤中的表达水平 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 股票代码：688505 股票简称：复旦张江 公告编号：临 2023-040 上海复旦张江生物医药股份有限公司 关于召开 2023 年半年度业绩说明会的公告 重要内容提示： 1 / 2 投资者可于 2023 年 08 月 04 日（周五）至 08 月 10 日（周四）16:00 前登录 上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ir@fd-zj.com 进 行提问。公司将在说明会上对投资者普遍关注的问题进行回答。 上海复旦张江生物医药股份有限公司（以下简称"公司"）将于 2023 年 8 月 11 日于上海证券交易所网站（www.sse.com.cn）披露《上海复旦张江生物医药股 份有限公司 2023 年半年度报告》。为便于广大投资者全面深入地了解公司 2023 年半年度经营成果、财务状况及发展理念，公司计划于 2023 年 08 月 11 日下午 14:00-15:00 举行 2023 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 189,147,552, representing a year-on-year increase of 34.33%[5] - The net profit attributable to shareholders for the same period was CNY 8,787,158, reflecting a significant increase of 78.39% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses surged by 252.85% to CNY 2,349,656[5] - Total operating revenue for Q1 2023 reached ¥189,147,552, a 34.3% increase from ¥140,805,956 in Q1 2022[17] - Net profit for Q1 2023 was ¥8,794,123, compared to a net profit of ¥4,810,020 in Q1 2022, representing a 83.5% increase[18] - The total comprehensive income for Q1 2023 was ¥8,449,017, compared to ¥4,347,867 in Q1 2022, marking a 94.5% increase[19] Research and Development - Research and development expenses totaled CNY 54,511,436, accounting for 28.82% of operating revenue, a decrease of 6.49 percentage points compared to the previous year[6] - Research and development expenses were ¥54,123,028, an increase of 11.0% from ¥48,439,435 in the same period last year[17] Assets and Liabilities - The total assets at the end of the reporting period were CNY 2,850,342,292, down 4.22% from the end of the previous year[6] - As of March 31, 2023, the total assets of Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. amounted to CNY 2,850,342,292, a decrease from CNY 2,976,007,272 at the end of 2022[13] - The company's current assets decreased to CNY 1,863,871,518 from CNY 2,069,188,785, reflecting a decline of approximately 9.94%[13] - The total liabilities decreased to CNY 588,372,864 from CNY 722,985,917, representing a reduction of approximately 18.6%[15] - The company's equity attributable to shareholders increased slightly to CNY 2,266,043,325 from CNY 2,257,102,217, showing a growth of about 0.35%[15] - The company reported a decrease in non-current liabilities to CNY 45,699,858 from CNY 49,641,713, a decline of approximately 7.4%[15] Cash Flow - The net cash flow from operating activities was negative at CNY -160,260,214, primarily due to payments made for accounts payable from the previous year[8] - Cash flow from operating activities totaled ¥162,901,241, down from ¥200,904,381 in Q1 2022, indicating a decrease of 18.9%[21] - The net cash flow from operating activities was -$160.26 million, compared to -$17.21 million in the previous period, indicating a significant increase in cash outflow[23] - The net increase in cash and cash equivalents for the first quarter was -$401.29 million, compared to -$59.13 million in the previous year[24] - The ending balance of cash and cash equivalents was $888.01 million, down from $1.15 billion at the end of the previous period[24] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 21,986[10] - Major shareholders included HKSCC NOMINEES LIMITED with 22.24% ownership and Shanghai Pharmaceutical Group with 20.42% ownership[10] - The number of shareholders as of the report date was 21,986, with 21,849 holding A shares and 137 holding H shares[11] Other Information - The company reported non-recurring gains of CNY 6,437,502, which included government subsidies and asset disposal gains[7] - The company has not disclosed any significant new strategies or product developments in the current report[12] - The company has not adopted new accounting standards for the current year, maintaining consistency in financial reporting[24] - The cash flow from operating activities reflects challenges in generating positive cash flow, which may impact future operational strategies[23] - The company continues to monitor its cash position closely amid fluctuating cash flows from various activities[24]

Financial Performance - Revenue for the first quarter reached RMB 189,147,552, representing a year-on-year increase of 34.33%[2] - Net profit attributable to shareholders was RMB 8,787,158, an increase of 78.39% compared to the same period last year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 2,349,656, reflecting a significant increase of 252.85%[2] - Operating profit for Q1 2023 was 3,481,590, a significant recovery from a loss of 1,492,333 in Q1 2022[11] - Net profit for Q1 2023 was 8,794,123, compared to 4,810,020 in Q1 2022, reflecting a year-over-year increase of 83.5%[11] - The company reported a basic and diluted earnings per share of 0.01 for Q1 2023, compared to 0.00 in Q1 2022[11] Research and Development - Research and development expenses totaled RMB 54,511,436, accounting for 28.82% of revenue, a decrease of 6.49 percentage points from the previous year[2] - Research and development expenses increased to 54,123,028, up from 48,439,435, indicating a focus on innovation[11] Assets and Liabilities - Total assets at the end of the reporting period were RMB 2,850,342,292, a decrease of 4.22% from the end of the previous year[2] - Total current assets decreased to 1,863,871,518 from 2,069,188,785, a decline of 9.9%[9] - Total liabilities decreased from 722,985,917 to 588,372,864, a reduction of 18.6%[10] - Cash and cash equivalents decreased from 1,289,302,664 to 888,009,829, a decline of 31.1%[9] - Total assets decreased from 2,976,007,272 to 2,850,342,292, a decline of 4.2%[10] Cash Flow - The net cash flow from operating activities was negative at RMB -160,260,214, primarily due to payments made to suppliers from the previous year[4] - In Q1 2023, cash inflow from operating activities was 162,901,241, down 18.9% from 200,904,381 in Q1 2022[13] - Cash outflow for purchasing goods and services increased significantly to 228,636,546, compared to 112,337,883 in the same period last year, representing a 103.6% increase[13] - Net cash flow from operating activities was -160,260,214, worsening from -17,207,380 in Q1 2022[13] - Cash inflow from investment activities totaled 1,055,510,659, slightly up from 1,054,566,056 in Q1 2022[13] - Cash outflow for investment activities rose to 1,291,246,012, compared to 1,094,314,314 in the previous year, marking an 18% increase[13] - Net cash flow from investment activities was -235,735,353, compared to -39,748,258 in Q1 2022[13] - Cash flow from financing activities resulted in an outflow of 5,251,044, up from 2,161,665 in Q1 2022[13] - The net increase in cash and cash equivalents was -401,292,835, compared to -59,130,975 in the same quarter last year[13] - The ending balance of cash and cash equivalents was 888,009,829, down from 1,149,749,936 in Q1 2022[13] Shareholder Information - The company reported a total of 21,986 shareholders at the end of the reporting period[6] Government Subsidies - The company received government subsidies amounting to RMB 3,216,857, which are closely related to its normal business operations[3] Product and Market Development - Major products sales improved during the reporting period, contributing to the overall revenue growth[4] - The company has not reported any new products or technologies, market expansions, or mergers in this quarter[14]

Financial Performance - Total revenue for 2022 was RMB 1,031,160,000, a decrease of 9.6% compared to RMB 1,140,313,000 in 2021[7] - Profit before tax for 2022 was RMB 132,294,000, down 38.8% from RMB 215,921,000 in 2021[7] - Net profit attributable to shareholders for 2022 was RMB 137,997,000, a decrease of 35.4% compared to RMB 213,296,000 in 2021[7] - The basic and diluted earnings per share attributable to shareholders for 2022 was RMB 0.1340, down from RMB 0.2049 in 2021[7] - The company's net profit for 2022 was approximately RMB 137,272 thousand, a decline of about 35% from RMB 212,381 thousand in 2021, resulting in a net profit margin of 13% compared to 19% in the previous year[79] - The cost of goods sold for 2022 was RMB 84,062 thousand, up from RMB 80,899 thousand in 2021, with the cost-to-revenue ratio increasing from 7% to 8%[68] - Sales expenses for 2022 were RMB 554,631 thousand, an 8% decrease from RMB 599,697 thousand in 2021, while the ratio of sales expenses to revenue increased from 53% to 54%[69] - Research and development expenses for 2022 amounted to RMB 226,851 thousand, a 1% increase from RMB 224,387 thousand in 2021, while total R&D investment decreased by 6% to RMB 233,659 thousand[70] - Other income for 2022 was RMB 10,465 thousand, a decrease of 52% from RMB 21,687 thousand in 2021, attributed to a reduction in government subsidies[75] Assets and Liabilities - Total assets as of December 31, 2022, were RMB 2,976,007,000, an increase of 7% from RMB 2,781,172,000 in 2021[9] - Total liabilities as of December 31, 2022, were RMB 722,986,000, an increase of 22.2% from RMB 591,582,000 in 2021[9] - As of December 31, 2022, the company's long-term equity investments had a net book value of RMB 305,767 thousand, with an investment loss of approximately RMB 19,800 thousand recorded during the reporting period[81] - As of December 31, 2022, the company had cash and cash equivalents of approximately RMB 1,289,303 thousand, an increase from RMB 1,208,881 thousand at the end of 2021[94] Research and Development - The company aims to become an innovator and leader in the biopharmaceutical industry, focusing on effective treatment solutions[12] - The company emphasizes the importance of new drug development as a reflection of value creation in the pharmaceutical industry[12] - The company plans to continue exploring clinical treatment gaps and providing more effective therapeutic options[12] - The company has a strong commitment to addressing unmet clinical needs through innovative drug development[16] - The company has established a gene engineering technology platform, focusing on developing cytokine, fusion protein, monoclonal antibody, and antibody-drug conjugate products to meet unmet clinical needs[174] - The company has established a nanotechnology platform for drug development, focusing on liposomal formulations to enhance drug solubility and bioavailability, addressing significant technical barriers in the industry[177] - The company has maintained a balance between innovative and generic drug development, ensuring that its projects meet clinical needs and demonstrate unique therapeutic effects[171] Clinical Trials and Product Development - The company is a leader in the development of photodynamic drugs, with ongoing research targeting skin diseases, tumors, and precancerous lesions[16] - The product ALA® has been successfully commercialized and is now the preferred clinical drug for treating condyloma acuminatum, with multiple new indications being explored[17] - Clinical research for ALA® in treating cervical precancerous lesions has shown significant progress, with a new optimized Phase II clinical study plan developed[20] - The company is conducting Phase II clinical trials for ALA® in treating moderate to severe acne, focusing on pain-free treatment options[20] - The company has initiated Phase II clinical trials for ALA® in treating glioblastoma, confirming its potential clinical benefits[20] - The product Revamed® (Heimofen) is the world's first photodynamic drug for treating capillary malformations, with ongoing Phase II clinical trials in the U.S.[22] - The company's first ADC drug, targeting CD30, completed Phase I clinical trials and is now undergoing an expansion Phase I trial for relapsed/refractory CD30-positive peripheral T-cell lymphoma[26] - The ADC drug targeting Trop2 for triple-negative breast cancer, bladder cancer, and gastric cancer is currently in Phase I clinical research, aiming to achieve similar clinical results as the original drug[28] - The ADC drug targeting HER2 for metastatic breast cancer and gastric cancer has initiated Phase I clinical research, with the first subject enrolled in January 2023[29] - The company has developed a new linker-drug platform (BB05 platform) to support the development of Me-better or innovative ADC drugs[28] - The Parkinson's disease controlled-release drug project (WD-1603) completed Phase II clinical research and is expected to enter Phase III trials soon, utilizing the UGi-Pump® technology[30] - The small molecule JAK1 selective inhibitor for rheumatoid arthritis is currently in Phase I clinical research, with additional projects for atopic dermatitis and ulcerative colitis in Phase II[31] - The company has received approval for a topical JAK1 selective inhibitor for atopic dermatitis to commence Phase I clinical trials[31] Market and Industry Trends - The global pharmaceutical market is projected to exceed USD 1.1 trillion by 2024, with a compound annual growth rate of 3-6% expected until 2026[59] - By 2025, the Chinese pharmaceutical market is estimated to reach RMB 2.1 trillion, with the biopharmaceutical market expected to account for 48%[59] - The market for broad skin disease treatment and care in China grew from RMB 300.4 billion in 2017 to RMB 471.8 billion in 2021, with a CAGR of 11.95%[153] - The global oncology drug expenditure is projected to reach $370 billion by 2027, driven by the acceleration of new drug launches and biosimilars[157] - In China, approximately 2.2 million new cancer cases are reported annually, with a mortality rate of 1.6 million, indicating a 20% annual increase in incidence and mortality over the past two decades[157] Corporate Governance and Strategy - The company emphasizes the importance of balancing innovative drug development with shareholder interests[14] - The company has implemented a restricted stock incentive plan in 2021, incurring share-based payment expenses of approximately RMB 7,689 thousand during the reporting period[79] - The company believes that the structured deposit agreements with banks will yield more favorable returns compared to traditional deposits[114] - The board of directors has approved the incentive plan to enhance the motivation and creativity of the employees involved[118] - The company has a conservative financial policy, focusing on centralized management of funds and regular assessments of asset liquidity and financial arrangements[94] - The company has no significant contingent liabilities or asset pledges as of December 31, 2022[86][87] Challenges and Risks - The company faced challenges in production and sales due to unexpected factors, impacting the normal operation of research and development projects[65] - The company faces risks related to new drug development, with a lengthy process that can take over ten years and significant uncertainty regarding the success of products in clinical trials[185] - The company’s product range is relatively narrow, with three main products contributing significantly to total revenue, which poses a risk if these products face competitive pressures or regulatory challenges[187] - Recent policies have led to a decline in drug prices, increasing competition and potential revenue impacts for the company, although its products are not currently subject to these price reductions[188] Dividend Policy - The company plans to distribute a final dividend of RMB 0.07 per share for the year ended December 31, 2022, totaling approximately RMB 72.03 million (including tax) based on 1,029,000,000 shares issued[197] - The proposed dividend distribution will be subject to approval at the annual general meeting scheduled for May 30, 2023[197] - The company has implemented a stable and proactive profit distribution policy since 2015, aiming for a cash dividend ratio of no less than 10% of the distributable profit in the first three years post-IPO[194] - The board of directors will consider the impact of cash dividends on the company's operational funding needs and any significant cash expenditures in the next twelve months[196]

股票代码：688505 股票简称：复旦张江 公告编号：临 2023-015 上海复旦张江生物医药股份有限公司 关于参加 2022 年度集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2023 年 4 月 25 日（周二）前通过邮件（ir@fd-zj.com）将需要了 解和关注的问题提前提供给公司，公司将在文字互动环节对投资者普遍关注的问 题进行回答。 上海复旦张江生物医药股份有限公司（以下简称"公司"）已于 2023 年 3 月 28 日于上海证券交易所网站（www.sse.com.cn）披露《上海复旦张江生物医药股 份有限公司 2022 年年度报告》。为便于广大投资者全面深入地了解公司 2022 年 度经营成果、财务状况、发展理念，公司参与了由上海证券交易所主办的 2022 年度集体业绩说明会，此次活动将采用视频和网络文字互动的方式举行，投资者 可登录上海证券交易所上证路演中心（http://roadshow.sseinfo.com/）参与线上互 动交流。 一、说明会类型 ...

Financial Performance - The company's operating revenue for 2022 was CNY 1,031,159,838, a decrease of 9.57% compared to CNY 1,140,313,088 in 2021[21]. - The net profit attributable to shareholders for 2022 was CNY 137,997,098, down 35.30% from CNY 213,295,758 in 2021[21]. - The net cash flow from operating activities was CNY 165,268,622, reflecting a decline of 38.54% compared to CNY 268,899,775 in 2021[21]. - The total assets at the end of 2022 were CNY 2,976,007,272, an increase of 7.01% from CNY 2,781,172,268 at the end of 2021[21]. - The basic earnings per share for 2022 were CNY 0.13, a decrease of 38.10% from CNY 0.21 in 2021[22]. - The diluted earnings per share for 2022 were CNY 0.13, down 35.00% from CNY 0.20 in 2021[22]. - The weighted average return on equity decreased to 6.21% in 2022, down 4.21 percentage points from 10.42% in 2021[22]. - The net assets attributable to shareholders at the end of 2022 were CNY 2,257,102,217, a slight increase of 2.93% from CNY 2,192,945,932 at the end of 2021[21]. Dividend and Share Capital - The proposed cash dividend for the year 2022 is RMB 0.7 per share, totaling RMB 72,030,000, which accounts for 52.20% of the net profit attributable to shareholders[5]. - The total share capital as of December 31, 2022, is 1,029,000,000 shares[5]. - The company does not plan to increase capital reserves or issue bonus shares[5]. Research and Development - The company's R&D expenditure accounted for 22.66% of operating revenue in 2022, an increase of 0.90 percentage points from 21.76% in 2021[22]. - The company reported a total R&D investment of ¥233,659,132, a decrease of 5.84% compared to the previous year[74]. - The number of newly applied patents during the year was 15, with a total of 187 applications and 104 patents granted cumulatively[72]. - The company has 184 R&D personnel, representing 20.22% of the total workforce, an increase from 17.65% in the previous year[83]. - The company’s R&D projects are primarily focused on addressing unmet clinical needs and demonstrating unique therapeutic effects[84]. - The company is advancing multiple antibody-drug conjugates, such as Trop2 antibody conjugate (F0024) and DLL3 antibody conjugate (F0041), both at Phase I and preclinical stages, indicating strong R&D capabilities[85]. Market and Industry Trends - The global pharmaceutical market is projected to grow at a compound annual growth rate of 3-6% from 2023 to 2027, potentially reaching a total market size of approximately USD 1.9 trillion[46]. - The Chinese pharmaceutical market reached a total size of USD 221.4 billion in 2020, with projections to grow to USD 349.8 billion by 2025[47]. - The market for broad skin disease treatment and care in China grew from RMB 300.4 billion in 2017 to RMB 471.8 billion in 2021, with a compound annual growth rate of 11.95%[48]. - The aging population in China is projected to increase the demand for pharmaceuticals, with the population aged 65 and above rising from 170 million in 2018 to 210 million in 2022, accounting for 14.86% of the total population[9]. Product Development and Pipeline - The company is focusing on innovative drug development using gene engineering, photodynamic technology, and nanotechnology, targeting skin diseases and tumors[33]. - The company plans to expand its clinical indications for selected drugs and develop new treatment regimens[33]. - The company aims to become a leader in the biopharmaceutical industry by providing effective treatment solutions and drugs[34]. - The company is conducting clinical trials for multiple projects, including the successful registration of Haemophin in the U.S. market[78]. - The company is advancing its ADC projects, including a Phase I clinical trial for an anti-Trop2 ADC drug targeting triple-negative breast cancer and bladder cancer[146]. Risks and Challenges - The company has disclosed potential significant risks in the management discussion and analysis section[4]. - The company faces risks related to the successful development and commercialization of new drugs, which can take over ten years and involve significant costs[93]. - The company is at risk of losing core technical personnel, which could impact its competitive advantage and operational stability if not managed effectively[94]. Governance and Compliance - The audit report issued by PwC is a standard unqualified opinion[5]. - The company has not violated decision-making procedures for external guarantees[7]. - The absence of a controlling shareholder poses risks to corporate governance and decision-making efficiency[95]. - The company is focusing on governance improvements through the revision of its management methods and rules[195].

Financial Performance - The company's revenue for the year ended December 31, 2022, was RMB 1,031,160,000, a decrease of 9.6% compared to RMB 1,140,313,000 in 2021[2] - Profit before tax for 2022 was RMB 132,294,000, down 38.7% from RMB 215,921,000 in the previous year[2] - The total comprehensive income attributable to shareholders for 2022 was RMB 136,847,000, a decline of 34.8% from RMB 210,016,000 in 2021[2] - The company's basic and diluted earnings per share for 2022 were RMB 0.1340, down from RMB 0.2049 in 2021, reflecting a decrease of 34.3%[2] - Net profit for 2022 was RMB 137,272,198, down from RMB 212,380,705 in 2021, representing a decline of 35.3%[13] - Total revenue for 2022 was $929.03 million, a decrease of 8.96% from $1,020.67 million in 2021[18] - Net profit for 2022 was $102.04 million, down 41.06% from $173.22 million in 2021[18] - Operating profit decreased to $105.92 million in 2022, compared to $177.03 million in 2021, reflecting a decline of 40.06%[18] Assets and Liabilities - The company's total assets as of December 31, 2022, amounted to RMB 2,976,007,000, an increase from RMB 2,781,172,000 in 2021[4] - Total liabilities increased to RMB 722,986,000 in 2022 from RMB 591,582,000 in 2021, representing a rise of 22.2%[4] - The company's total liabilities reached RMB 678,689,845 in 2022, an increase of 25.9% from RMB 539,099,929 in 2021[11] - Current liabilities rose to RMB 633,102,882 in 2022, compared to RMB 482,246,500 in 2021, an increase of 31.3%[11] - The company's total equity attributable to shareholders was RMB 2,257,102,000 as of December 31, 2022, compared to RMB 2,192,946,000 in 2021, showing an increase of 2.9%[8] Cash and Cash Equivalents - Cash and cash equivalents as of December 31, 2022, were RMB 1,289,302,664, up from RMB 1,208,880,911 in 2021[6] - Cash flow from operating activities for 2022 was $165.27 million, a decrease of 38.43% from $268.90 million in 2021[21] - The company reported cash and cash equivalents at year-end 2022 of $1.29 billion, an increase from $1.21 billion at the end of 2021[23] - Cash and bank deposits as of December 31, 2022, amount to RMB 1,289,258,185, an increase from RMB 1,208,855,545 in 2021[126] Research and Development - Research and development expenses increased slightly to RMB 226,850,903 in 2022 from RMB 224,387,287 in 2021, indicating a focus on innovation[13] - Research and development expenditures are classified into research phase and development phase, with development costs capitalized only if specific criteria are met[87] - Research and development expenses for 2022 totaled RMB 233,659,132, a decrease from RMB 248,153,842 in 2021, with RMB 226,850,903 recognized in profit or loss[178] Shareholder Equity and Dividends - The company distributed RMB 72,030,000 to shareholders in 2022, compared to RMB 52,150,000 in 2021, marking an increase of approximately 38.3%[34] - The total comprehensive income for 2022 was RMB 137,272,198, down from RMB 212,380,706 in 2021, reflecting a decrease of approximately 35.3%[34] - The company reported a total shareholder equity of RMB 2,321,921,130 as of December 31, 2022, reflecting a slight increase from the previous year[34] Inventory and Receivables - The company reported a decrease in inventory to RMB 40,526,760 in 2022 from RMB 35,625,222 in 2021, which is an increase of 13.4%[6] - The total accounts receivable balance as of December 31, 2022, is CNY 569,136,087, with an expected credit loss of CNY 14,777,342[138] - Accounts receivable as of December 31, 2022, total RMB 518,749,422, down from RMB 569,136,087 in 2021, indicating a decrease of approximately 8.8%[129] - The provision for bad debts for accounts receivable decreased to RMB 12,365,732 in 2022 from RMB 14,777,342 in 2021, reflecting a reduction of about 16.3%[133] Impairment and Provisions - The total impairment provision for assets decreased to CNY 16,229,937 from CNY 17,178,928 in 2021, reflecting a reduction of approximately 5.5%[190] - The provision for inventory write-down increased by CNY 3,052,947 during the year, resulting in a total of CNY 3,247,315 as of December 31, 2022, compared to CNY 4,771,622 in 2021[190] - The provision for bad debts for other receivables was zero as of December 31, 2022, compared to CNY (925) in 2021[151] Employee Compensation - The total employee compensation payable decreased to CNY 27,761,585 in 2022 from CNY 36,493,188 in 2021, reflecting a decline of about 24.5%[197] - The provision for employee benefits, including social insurance, was CNY 2,280,771 as of December 31, 2022, compared to CNY 491,727 in 2021, indicating a significant increase in employee-related expenses[199] Accounting Policies - The financial statements for the year 2022 were approved by the board of directors on March 27, 2023[41] - The company adheres to the accounting standards set by the Ministry of Finance and the China Securities Regulatory Commission, ensuring the financial statements reflect true and complete information[44] - The accounting year runs from January 1 to December 31, aligning with the calendar year[45] Other Financial Information - The company has adopted new accounting standards and interpretations issued by the Ministry of Finance, which had no significant impact on the financial statements[120] - The corporate income tax rate applicable to the company for the year 2022 is 15%, consistent with 2021[122] - The company has not recognized any taxable income for its subsidiary Taizhou Fudan Zhangjiang Pharmaceutical Co., Ltd. for the years 2021 and 2022, resulting in no income tax expense[123]

Group 1: Company Overview - Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. was established in November 1996 and is primarily engaged in innovative research, development, manufacturing, and marketing in the biopharmaceutical sector [2]. - The company aims to be an innovator and leader in the biopharmaceutical industry, focusing on exploring clinical treatment gaps and providing more effective therapeutic solutions [2]. Group 2: Research and Development Platforms - The company has established multiple research platforms, including gene engineering, photodynamic technology, nanotechnology, and oral solid preparation technology [4]. - The research pipeline includes various indications, with a focus on antibody-drug conjugates (ADC) targeting cancers such as breast cancer and gastric cancer [5]. Group 3: Product Development and Clinical Trials - The main component of the drug Aira is aminolevulinic acid hydrochloride, with ongoing studies for indications including HPV-related cervical diseases and acne, with some projects already in Phase II clinical trials [3]. - The photodynamic therapy products Aira and Fumeida have shown significant clinical advantages over traditional laser treatments, including lower recurrence rates and better patient tolerance [4]. Group 4: Financial and Investment Insights - R&D investment has been increasing since the company's listing on the STAR Market, with R&D expenditure as a percentage of revenue rising from 12.68% in 2019 to 21.76% in 2021 [6]. - The company plans to maintain a high R&D investment ratio in the future, continuing to focus on advancing ongoing projects [6].